| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = -$109,415 ) |
| | 2023 | 2020 | ACUMEN PHARMACEUTICALS, INC. | 427 PARK ST | CHARLOTTESVILLE | VA | 22902-4737 | CHARLOTTESVILLE CITY | USA | U01AG053247 | Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development | 002 | 4 | NIH | 3/17/2023 | -$82,309 |
| | 2023 | 2020 | ACUMEN PHARMACEUTICALS, INC. | 427 PARK ST | CHARLOTTESVILLE | VA | 22902-4737 | CHARLOTTESVILLE CITY | USA | U01AG053247 | Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development | 001 | 4 | NIH | 3/17/2023 | $55,202 |
| | 2023 | 2020 | ACUMEN PHARMACEUTICALS, INC. | 427 PARK ST | CHARLOTTESVILLE | VA | 22902-4737 | CHARLOTTESVILLE CITY | USA | U01AG053247 | Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development | 000 | 4 | NIH | 3/17/2023 | -$82,309 |
|
| Issue Date FY: 2020 ( Subtotal = $1,059,587 ) |
| | 2020 | 2020 | ACUMEN PHARMACEUTICALS, INC. | 427 PARK ST | CHARLOTTESVILLE | VA | 22902-4737 | CHARLOTTESVILLE CITY | USA | U01AG053247 | Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development | 002 | 4 | NIH | 8/14/2020 | -$262,500 |
| | 2020 | 2020 | ACUMEN PHARMACEUTICALS, INC. | 427 PARK ST | CHARLOTTESVILLE | VA | 22902-4737 | CHARLOTTESVILLE CITY | USA | U01AG053247 | Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development | 000 | 4 | NIH | 7/1/2020 | $797,087 |
| | 2020 | 2020 | ACUMEN PHARMACEUTICALS, INC. | 427 PARK ST | CHARLOTTESVILLE | VA | 22902-4737 | CHARLOTTESVILLE CITY | USA | U01AG053247 | Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development | 001 | 4 | NIH | 8/10/2020 | $262,500 |
| | 2020 | 2020 | ACUMEN PHARMACEUTICALS, INC. | 427 PARK ST | CHARLOTTESVILLE | VA | 22902-4737 | CHARLOTTESVILLE CITY | USA | U01AG053247 | Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development | 002 | 4 | NIH | 8/14/2020 | $262,500 |
|
| Issue Date FY: 2019 ( Subtotal = $1,135,517 ) |
| | 2019 | 2019 | ACUMEN PHARMACEUTICALS, INC | 657 RIDGECREST CIR | LIVERMORE | CA | 94551-0154 | ALAMEDA | USA | U01AG053247 | Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development | 000 | 3 | NIH | 8/16/2019 | $1,135,517 |
| | 2019 | 2016 | ACUMEN PHARMACEUTICALS, INC | 657 RIDGECREST CIR | LIVERMORE | CA | 94551-0154 | ALAMEDA | USA | R41AG054337 | Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer. | 000 | 1 | NIH | 10/25/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,256,516 ) |
| | 2018 | 2018 | ACUMEN PHARMACEUTICALS, INC | 657 RIDGECREST CIR | LIVERMORE | CA | 94551-0154 | ALAMEDA | USA | U01AG053247 | Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development | 000 | 2 | NIH | 8/31/2018 | $1,256,516 |
|
| Issue Date FY: 2017 ( Subtotal = $444,503 ) |
| | 2017 | 2017 | ACUMEN PHARMACEUTICALS, INC | 657 RIDGECREST CIR | LIVERMORE | CA | 94551-0154 | ALAMEDA | USA | U01AG053247 | Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development | 000 | 1 | NIH | 9/15/2017 | $444,503 |
|
| Issue Date FY: 2016 ( Subtotal = $222,192 ) |
| | 2016 | 2016 | ACUMEN PHARMACEUTICALS INC | 4435 NORTH FIRST STREET | LIVERMORE | CA | 94551 | ALAMEDA | USA | R41AG054337 | Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer. | 000 | 1 | NIH | 9/6/2016 | $222,192 |
|
| Issue Date FY: 2015 ( Subtotal = -$176,145 ) |
| | 2015 | 2014 | ACUMEN PHARMACEUTICALS INC | 4435 NORTH FIRST STREET | LIVERMORE | CA | 94551 | ALAMEDA | USA | R43AG047691 | Development and validation of a sensitive and selective assay for quantitating so | 000 | 1 | NIH | 12/18/2014 | -$176,145 |
|
| Issue Date FY: 2014 ( Subtotal = $176,145 ) |
| | 2014 | 2014 | ACUMEN PHARMACEUTICALS INC | 4435 NORTH FIRST STREET | LIVERMORE | CA | 94551 | ALAMEDA | USA | R43AG047691 | Development and validation of a sensitive and selective assay for quantitating so | 000 | 1 | NIH | 9/16/2014 | $176,145 |
|
| Issue Date FY: 2005 ( Subtotal = $329,524 ) |
| | 2005 | 2005 | ACUMEN PHARMACEUTICALS INC | 385 OYSTER POINT BOULEVARD | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R43AG026190 | BIOMARKER FOR ALZHEIMER'S RELATED COGNITIVE DEFICITS | 000 | 1 | NIH | 7/29/2005 | $145,774 |
| | 2005 | 2005 | ACUMEN PHARMACEUTICALS INC | 385 OYSTER POINT BOULEVARD | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R43AG026951 | DRUG DISCOVERY OF ANTI-ADDL THERAPEUTICS FOR ALZHEIMER'S | 000 | 1 | NIH | 9/12/2005 | $183,750 |
|
|
